# Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-analysis-of-baricitinib-versus-dupilumab-for-moderate-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Erin Johansson,Massimo Giovannitti,Maurizio Mezzetti,Na Lu,Silvia Sabatino |
| Citations | 3 |
| DOI | 10.1080/13696998.2023.2255495 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | http://dx.doi.org/10.1080/13696998.2023.2255495 |
| OpenAlex ID | https://openalex.org/W4386501964 |
| PMID | 37674383 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Silvia Sabatino](https://scholariq.org/researchers/silvia-sabatino/)

## Paper journal

- [Journal of Medical Economics](https://scholariq.org/journals/journal-of-medical-economics/)

## Paper primary topic

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Paper topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.